Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
QBIO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
proactiveinvestors.com
9 hours ago
proactiveinvestors.com
9 hours ago
proactiveinvestors.com
9 hours ago
proactiveinvestors.com
10 hours ago
proactiveinvestors.com
10 hours ago
proactiveinvestors.ca
11 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.21
N/A
-0.07
vs NA
Q4.21
N/A
-0.08
vs -0.15
Q1.22
N/A
-0.08
vs -0.11
Q2.22
N/A
-0.06
vs -0.08
Q3.22
N/A
-0.03
vs -0.07
Q4.22
+200%
0.08
vs -0.08
Q1.23
N/A
-0.02
vs -0.08
Q2.23
N/A
NA
vs NA
Q3.23
+4727%
1.39
vs -0.03
Q4.23
+2511%
2.09
vs 0.08
Sales Growth
YoY
Current
Estimates
Q3.21
+205%
45.7K vs 15K
Q4.21
NA
104.9K vs NA
Q1.22
+85%
75.1K vs 40.6K
Q2.22
+279%
170.5K vs 45K
Q3.22
-42%
26.3K vs 45.7K
Q4.22
-88%
12.5K vs 104.9K
Q1.23
-97%
2.5K vs 75.1K
Q2.23
NA
NA vs NA
Q3.23
-89%
2.9K vs 26.3K
Q4.23
-75%
3.2K vs 12.5K
Return on Equity
QoQ
Q4.20
+319%
3.19
vs -17.83
Q1.21
+139%
1.39
vs 3.19
Q2.21
+87%
0.87
vs 1.39
Q3.21
+60%
0.6
vs 0.87
Q4.21
+44%
0.44
vs 0.6
Q1.22
+59%
0.59
vs 0.44
Q2.22
+27%
0.27
vs 0.59
Q3.22
+11%
0.11
vs 0.27
Q4.22
-50%
-0.50
vs 0.11
Q1.23
+13%
0.13
vs -0.50
Institutionnal Ownership
QoQ
Q1.19
1
1
vs NA
NA
Q2.19
NA
NA
vs NA
NA
Q3.19
1
1
vs NA
NA
Q4.19
1
1
vs 1
NA
Q1.20
NA
NA
vs NA
NA
Q2.20
1
1
vs NA
NA
Q3.20
1
1
vs 1
NA
Q4.20
1
1
vs 1
NA
Q1.21
1
1
vs 1
NA
Q2.21
1
1
vs 1
NA
Relative Strength
QBIO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
OTC
Unprofitable
Unprofitable
Relative Strenght
Volume Buzz
26%
Earning Acce
No
Dist 52w H.
100%Forecast
2025-Revenue
2025-EPS
2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Hold
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
No Data Available